Tag: Senseonics
Ascensia extends PASS program
March 14, 2024HME News Staff
PARSIPPANY, N.J. – Ascensia Diabetes Care and Senseonics Holdings will extend the Eversense Payment Assistance and Simple Savings (PASS) Program. Designed to help people in the U.S. access the Eversense E3 CGM System more affordably, the program offers major savings for eligible individuals looking to experience the unique benefits of the only long-term CGM system available. Eligible individuals will pay only $99 out of pocket for an unlimited number of six-month Eversense E3 systems under...
Ascensia announces coverage expansion for CGM system
February 12, 2024HME News Staff
PARSIPPANY, N.J. – Ascensia Diabetes Care and Senseonics Holdings have announced that Medicare has significantly expanded access to the Eversense E3 CGM System with the implementation of local coverage determinations that provide access to implantable CGM for basal-only patients. Medicare coverage has been expanded for implantable CGMs to include all people with diabetes using insulin, removing the previous requirement for multiple inulin administrations per day. Coverage has also been updated...
Ascensia names leader for CGM business
February 6, 2024HME News Staff
TOKYO – PHC Holdings Corp., the parent company of Ascensia Diabetes Care, and Senseonics Holdings have announced that diabetes industry veteran Brian Hansen has been appointed to the newly created role of president of CGM at Ascensia Diabetes Care effective today, Feb. 6, 2024. Hansen will be responsible for the global commercialization and growth of the Eversense CGM, which is currently available in the U.S. and select European markets. “Eversense is a game-changer for people with diabetes...
Ascensia, Senseonics launch ad campaign
October 11, 2023HME News Staff
PARSIPPANY, N.J., and GERMANTOWN, Md. – Ascensia Diabetes Care and Senseonics Holdings have launched a new U.S. advertising and marketing campaign for the Eversense E3 CGM System. The “CGM for Real Life” campaign seeks to drive awareness of the Eversense E3, a six-month, implantable sensor, as well as the everyday challenges people with diabetes face. “This campaign is designed to challenge the status quo in continuous glucose monitoring, which for too long has meant self-insertion...
Senseonics’ Eversense E3 offers accurate 365-day performance
June 28, 2023HME News Staff
GERMANTOWN, Md. – Senseonics Holdings highlighted new clinical data demonstrating the safety and accuracy of its Eversense E3 CGM system during a presentation at the American Diabetes Association 83rd Scientific Session. “These data further bolster Eversense’s position as a leading CGM choice for people with diabetes,” said Francine Kaufman, M.D., Senseonics chief medical officer. “These recent studies are an important step forward as we continue to expand awareness...
Senseonics secures coverage from UnitedHealthcare
June 5, 2023HME News Staff
GERMANTOWN, Md. – Senseonics Holdings has announced that UnitedHealthcare will begin providing coverage for the Eversense E3 CGM System effective July 1, 2023, for people with Type 1 and insulin-requiring Type 2 diabetes. "The policy update from UnitedHealthcare marks an important milestone for increased access to long-term CGM for people with diabetes,” said Tim Goodnow, PhD, president and CEO for Senseonics. “With the addition of UnitedHealthcare, we are nearing all insured adults...
Eversense trial expands to pediatric diabetes patients
April 19, 2023HME News Staff
GERMANTOWN, Md. – The first pediatric patient in the ENHANCE clinical trial has been inserted with the Eversense 365-day system, said Senseonics Holdings, a medical technology company focused on the development of long-term implantable CGMs. “It’s a priority for Senseonics to extend the benefits of Eversense to the pediatric patient population,” said Francine Kaufman, MD, chief medical officer for Senseonics. “The differentiated features of our long-term implantable...
Senseonics gets next-gen approval
February 15, 2022HME News Staff
GERMANTOWN, Md. – Senseonics has announced approval by the U.S. Food and Drug Administration for its next-generation Eversense E3 CGM System. The Eversense E3, which includes proprietary sacrificial boronic acid technology to extend longevity to six months, is planned to be available in the U.S. through Ascensia Diabetes Care, the company’s global commercial partner, beginning in the second quarter of 2022. “We repeatedly hear from our patients with diabetes that what they desire...
Ascensia bets on CGMs
September 4, 2020Theresa Flaherty, Managing Editor
BASEL, Switzerland - Ascensia's new partnership with Senseonics is a big nod to continuous glucose monitors as the next best step in diabetes management.
In August, Ascensia partnered with Senseonics to distribute its implantable CGM systems, including the Eversense and Eversense XL and future generation products, broadening its product portfolio beyond blood glucose monitoring systems, including its popular Contour line.
“We certainly have a vision to be able to grow...
Ascensia partners with Senseonics on implantable CGMs
August 11, 2020HME News Staff
BASEL, Switzerland - PHC Holdings Corporation and Ascensia Diabetes Care have announced a strategic partnership with Senseonics Holdings, Inc., a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes. As part of the agreement, Ascensia will serve as the exclusive global distribution partner for Senseonics' CGM systems, including Eversense, Eversense XL and future generation products...